| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Hematologic System |
Recent Updates
Recently added Catalysts
Immix Biopharma, Inc.$11.11
+0.12 (+1.08%)
C 42Pipeline Score Fair Value Pharma · Commercial
Market Cap
477.73 M
EPS
-0.92
P/E Ratio
-
Value Trade
8.99 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.98 M
Operating CF
-9.83 M
Total Assets
95.82 M
Total Liabilities
11.45 M
Equity
84.36 M
D/E Ratio
12,345
-12.46 %
Week
-11.4 %
1 Month
14.03 %
3 Month
126.29 %
6 Month
75.6 %
5 Year
75.6 %
All Time
Cash Data
Cash Position
90.58 M
Monthly Burn
3.28 M
Runway
25.7 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.62 M
52 Week Range
1.87 - 11.61
% held by Insiders
23.49 %
% held by Institutions
43.59 %
Enterprise Value
388.19 M
Total Shares
54.41 M
Short %
21.75 %
Float Shares
36.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immix Biopharma, Inc.
173Total events
4Upcoming
34Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 4
Event history 169
Q3 2026
◆Topline ReadoutNXC-201Clinical Data
Topline NEXICART-2 results expected
relapsed/refractory AL Amyloidosissource ↗
Q3 2026
●BLA SubmissionNXC-201Regulatory Filing
BLA submission planned after topline results
relapsed/refractory AL Amyloidosissource ↗
May 22, 2026
May 21, 2026
▼Equity OfferingCorporate
Pricing of $150 million underwritten offering of common stock at $8.94 per share
May 21, 2026
▲Full ResultsNXC-201Clinical Data
Interim update: 95% CR rate, all four MRD-negative patients converted to CR
relapsed/refractory AL Amyloidosissource ↗
Q2 2026
◆Topline ReadoutNXC-201Clinical Data
Final topline clinical data readout expected Q2/Q3 2026
relapsed/refractory AL Amyloidosissource ↗
Mar 30, 2026
▲Enrollment CompleteNXC-201Trial
Enrollment completion of NEXICART-2 trial
relapsed/refractory AL Amyloidosissource ↗
Mar 8, 2026
◆Oral PresentationPresentation
Presentation at Leerink Partners 2026 Global Healthcare Conference
Jan 28, 2026
▲Breakthrough Therapy DesignationNXC-201Designation
FDA granted Breakthrough Therapy Designation for NXC-201
relapsed/refractory AL Amyloidosissource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $362M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored2.5x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankImmix Biopharma, Inc. carries a moderate pipeline score (42/100), with $905M risk-adjusted pipeline value, led by NXC-201 CAR-T in Light Chain (AL) Amyloidosis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NXC-201 CAR-T Monoclonal antibody | Light Chain (AL) Amyloidosis | Phase 1 | NCT06097832 | 59% | $718M | RECRUITING | 40 | STALLED | D (35) | Jan 1, 2039 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NXC-201 BreakthroughRMATOrphan | relapsed/refractory AL Amyloidosis | Phase 2 | 2026-05-21 | complete response rate: 95%; patients treated: 20; MRD negative patients: 4; CR patients: 19; relapses observed: 0 Read More | Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete r Read More | |
NXC-201 BreakthroughRMATOrphan | relapsed/refractory AL Amyloidosis | Phase 2 | 2026-05-21 | complete response rate: 95%; patients treated: 20; MRD negative patients: 4; CR patients: 19; relapses observed: 0 Read More | Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete r Read More | |
NXC-201 BreakthroughRMATOrphan | relapsed/refractory AL Amyloidosis | Phase 2 | 2026-05-21 | complete response rate: 95%; patients treated: 20; MRD negative patients: 4; CR patients: 19; relapses observed: 0 Read More | Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete r Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMMX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMMX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMMXImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma has successfully closed a $150 million underwritten offering of common stock, selling 16,778,524 shares at $8.94 each. The net proceeds from this offering are approximately $140.65 million, which will support the company's initiatives in treating AL Amyloidosis. The offering was well-received by prominent U.S. biotechnology institutional investors.
Read more →IMMXImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma announced a 95% complete response rate in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. All four MRD-negative patients converted to complete response within one year, with no relapses reported. The company plans to initiate a Phase 3 trial for newly diagnosed patients and expects to present further data in September 2026.
Read more →IMMXImmix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete r
Immix Biopharma has announced an interim update from its NEXICART-2 clinical trial, indicating a 95% complete response rate among the first 20 patients treated for relapsed/refractory AL Amyloidosis. All four MRD-negative patients converted to complete response, and there have been no relapses among patients who reached a complete response within one year of follow-up. The company plans to initiate a randomized Phase 3 trial targeting newly diagnosed AL Amyloidosis patients and anticipates presenting further updates in late September 2026.
Read more →IMMXImmix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma has announced a $150 million underwritten offering of 16,778,524 shares of its common stock priced at $8.94 per share. The proceeds are intended to fund the development of NXC-201, working capital, and other corporate purposes, with plans to meet operational needs until mid-2028. The offering is subject to customary closing conditions and is expected to finalize around May 22, 2026. The company is a leader in AL Amyloidosis treatment and NXC-201 has achieved breakthrough designation from the FDA for this indication.
Read more →IMMX▲ +11.4%on this news
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Immix Biopharma, a leader in treating relapsed/refractory AL Amyloidosis, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. The company will host institutional investor meetings and provide access to a replay of the event on their website. Their lead candidate, NXC-201, is under evaluation in a multi-center study and has received significant FDA designations.
Read more →IMMX▲ +5.3%on this news
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma has completed enrollment for its BLA-enabling NEXICART-2 trial for relapsed/refractory AL Amyloidosis, with topline results anticipated in Q3 2026. The company has also appointed a new Chief Medical Officer to oversee the BLA submission process. If successful, NXC-201 could become the first FDA-approved treatment for this condition.
Read more →IMMXImmix Biopharma to Participate in Upcoming Investor Conferences
Immix Biopharma, Inc. announced its participation in upcoming investor conferences, including the Leerink Partners 2026 Global Healthcare Conference and the Citizens Life Sciences Conference. Company management will host one-on-one meetings with interested investors. ImmixBio is recognized for its innovative CAR-T cell therapy, NXC-201, which targets relapsed/refractory AL Amyloidosis and has received significant regulatory designations.
Read more →IMMXImmix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma has been granted Breakthrough Therapy Designation by the FDA for NXC-201, aimed at treating relapsed/refractory AL Amyloidosis. This designation is based on positive interim results from the NEXICART-2 Phase 2 clinical trial. The company anticipates final data later this year, followed by a planned Biologics License Application submission.
Read more →IMMX▲ +7.3%on this news
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma, Inc. has announced the successful closing of an upsized underwritten offering of $100 million, which includes approximately 19.1 million shares of common stock and pre-funded warrants. The offering attracted notable interest from leading U.S. biotechnology institutional investors and mutual funds. Following the deduction of offering expenses, Immix expects to receive about $93.7 million in net proceeds, which will bolster its development efforts. The offering was managed by Morgan Stanley, with additional support from Citizens Capital Markets and Mizuho.
Read more →IMMX▲ +10.6%on this news· ran to +33% by day 3shared move
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma reported promising Phase 2 results for NXC-201 at ASH 2025, showing a 75% complete response rate in patients with relapsed/refractory AL Amyloidosis. The therapy may further improve outcomes, with predictions of a 95% response rate based on MRD negativity. A BLA submission is anticipated in 2026, reflecting significant advancements in treatment options.
Read more →IMMX▲ +10.6%on this news· ran to +33% by day 3shared move
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma has announced the pricing of an upsized $100 million underwritten offering of common stock and pre-funded warrants. The offering includes 19,117,646 shares priced at $5.10 each and is expected to close by December 9, 2025. Proceeds will fund the development of NXC-201 and support operational needs through mid-2027.
Read more →IMMX▲ +15.2%on this news
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the launch of NXC-201, a promising therapy for relapsed/refractory AL Amyloidosis. This disease currently lacks FDA-approved treatments, highlighting the urgency of NXC-201's introduction. The therapy has received both Regenerative Medicine Advanced Therapy and Orphan Drug Designations from the FDA, positioning it as a potential breakthrough in treatment.
Read more →IMMXImmix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial for relapsed/refractory AL Amyloidosis will be presented at ASH 2025. The trial aims to evaluate the efficacy of NXC-201, a CAR-T cell therapy. The market for AL Amyloidosis treatments is projected to grow significantly, highlighting the potential impact of this therapy.
Read more →IMMXImmix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma announced that interim results from its NXC-201 NEXICART-2 clinical trial will be presented at the ASH 2025 Annual Meeting. The trial focuses on treating relapsed/refractory AL Amyloidosis, a serious condition affecting organ function. The presentation is scheduled for December 7, 2025, highlighting the company's advancements in CAR-T cell therapy.
Read more →IMMXImmix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Immix Biopharma will present at the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10-12, 2025. The company will host a Fireside Chat and one-on-one investor meetings. Their lead candidate, NXC-201, has shown promising interim results in clinical trials and has received special designations from the FDA and EMA.
Read more →IMMX▲ +11.8%on this news
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
Immix Biopharma, a leader in relapsed/refractory AL Amyloidosis, will present a NXC-201 abstract at the ASH 67th Annual Meeting in December 2025. The company is conducting a multi-center study for NXC-201, which has received significant designations from regulatory bodies. However, there are risks associated with ongoing clinical trials and funding.
Read more →IMMXImmix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
Immix Biopharma will present at the 37th Annual Piper Sandler Healthcare Conference from December 2-4, 2025. The company will host one-on-one meetings with institutional investors and provide updates on its CAR-T therapy NXC-201, which has shown promising interim results in clinical trials. Immix has received regulatory designations that support its development efforts.
Read more →IMMXImmix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Immix Biopharma has announced that it has surpassed the 50% enrollment milestone in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. The trial is evaluating the CAR-T cell therapy NXC-201, which has generated significant interest among clinicians. The company aims to submit a Biologics License Application (BLA) to the FDA as it progresses with the trial.
Read more →IMMXNancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Immix Biopharma has appointed Nancy T. Chang to its Board of Directors. Dr. Chang, known for her leadership at Tanox, Inc., has a proven track record in biotechnology, having overseen the development of several successful drugs. Immix is focused on developing cell therapies for AL Amyloidosis, with its lead candidate NXC-201 currently in clinical trials.
Read more →IMMX▲ +5.1%on this newsshared move
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Immix Biopharma has secured a strategic investment from Goose Capital, led by Dr. Nancy T. Chang, a notable figure in biopharmaceuticals. This investment aims to support the development of Immix's lead candidate, NXC-201, for relapsed/refractory AL Amyloidosis. The collaboration is expected to enhance Immix's potential for commercialization and innovation in cell therapies.
Read more →IMMXImmix Biopharma to Present at the Stifel 2025 Healthcare Conference
Immix Biopharma will present at the Stifel 2025 Healthcare Conference from November 11-13, 2025, in New York. The company will host one-on-one meetings with institutional investors. Its lead candidate, CAR-T NXC-201, is under evaluation in a multi-center study for relapsed/refractory AL Amyloidosis. The therapy has received significant designations from regulatory agencies.
Read more →IMMX▼ -5.5%on this news· ran to -15% by day 3
Immix Biopharma Announces Other Serious Diseases Strategy
Immix Biopharma has announced its strategy to address Other Serious Diseases (OSD) with its CAR-T therapy NXC-201. The company is focused on completing the NEXICART-2 trial for relapsed/refractory AL Amyloidosis, with plans to partner on OSD programs. Promising clinical results could lead to significant advancements in treatment options.
Read more →IMMXImmix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
Immix Biopharma announced a class-leading safety profile for its CAR-T NXC-201 therapy, notably lacking neurotoxicity in low-volume disease cases. The company is progressing towards filing a Biologics License Application (BLA) for NEXICART-2, targeting relapsed/refractory AL Amyloidosis. Additionally, they have plans for potential expansion into other immune-mediated diseases. Key safety data will be presented at the American Society for Clinical Oncology (ASCO 2025).
Read more →IMMXImmix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Immix Biopharma has announced significant progress in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. The trial has expanded to include 18 clinical sites across the U.S. in response to the unmet medical need for effective therapies in this area. Interim results were recently discussed at ASCO 2025, showcasing the potential of their CAR-T cell therapy, NXC-201. The company is optimistic about approaching the submission for the first Biologics License Application in this orphan indication market.
Read more →IMMX▲ +8.2%on this news
Immix Biopharma Attends FDA CEO Forum in Washington DC
Immix Biopharma announced its participation in the FDA CEO Forum held on June 5, 2025, which aimed to collect feedback from industry leaders to enhance the FDA's regulatory framework. The event was led by FDA Commissioner Marty A. Makary and included discussions on facilitating patient access to innovative therapies. Immix Biopharma's executives expressed their appreciation for being part of this discussion, emphasizing a mutual commitment to an efficient regulatory environment that supports breakthroughs in treatment. The company continues to develop its lead CAR-T therapy, NXC-201, for AL Amyloidosis amidst an ongoing clinical trial.
Read more →IMMX▼ -18.8%on this newsshared move
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma announced positive interim results from its NEXICART-2 Phase 1/2 clinical trial for NXC-201 at ASCO 2025, achieving a complete response rate of 70% in relapsed/refractory AL Amyloidosis patients. No safety signals or relapses have been recorded to date, and Immix plans to file a Biologics License Application for FDA approval. The results were presented by Dr. Heather Landau from Memorial Sloan Kettering Cancer Center, emphasizing the potential of NXC-201 as a best-in-class therapy for this indication.
Read more →IMMX▼ -17.4%on this news
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma has expanded its clinical trial NEXICART-2 for relapsed/refractory AL Amyloidosis by adding 10 new sites, bringing the total to 14 actively enrolling locations. The company anticipates completing the trial ahead of schedule due to robust patient enrollment. NXC-201, a BCMA-targeted CAR-T therapy, has shown promising initial data. Furthermore, NEXICART-2's interim data will be presented at the upcoming ASCO 2025 meeting.
Read more →IMMX▲ +15.3%on this newsshared move
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial for NXC-201, which showed a complete response rate of 71% among treated patients with relapsed/refractory AL Amyloidosis. There were no relapses or safety issues observed thus far, reinforcing the therapy's efficacy and safety profile. The updated data will be presented at the upcoming ASCO Annual Meeting, as the company anticipates further developments in its BLA submission process and ongoing trials. This advancement signifies a potentially significant shift in treatment strategies for this patient population.
Read more →IMMXImmix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
Immix Biopharma is set to host a virtual Key Opinion Leader (KOL) event on June 3, 2025, to discuss interim clinical data for their NXC-201 therapy targeting relapsed/refractory AL Amyloidosis. This event is scheduled following an oral presentation at the 2025 ASCO meeting and will feature prominent doctors who will share their insights on clinical experiences and the evolving treatment landscape. The NEXICART-2 study, currently ongoing, aims to evaluate the safety and efficacy of NXC-201 in a specific patient population.
Read more →IMMXImmix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
Immix Biopharma announced that interim data from its NXC-201 NEXICART-2 trial will be presented at ASCO 2025. The trial focuses on treating relapsed/refractory AL Amyloidosis and aims to enroll 40 patients. The presentation will take place on June 3, 2025, in Chicago, showcasing the potential of NXC-201, which has received FDA designations.
Read more →IMMXImmix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
Immix Biopharma has announced that interim data from its NXC-201 NEXICART-2 clinical trial will be presented at ASCO 2025. This Phase 1/2 trial focuses on relapsed/refractory AL Amyloidosis and is expected to enroll 40 patients. NXC-201, a BCMA-targeted CAR-T therapy, is noted for its initial favorable performance in studies. The presentation will be made by Dr. Heather Landau, highlighting the ongoing efforts and regulatory designations associated with this therapy.
Read more →IMMXImmix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
Immix Biopharma has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T therapy NXC-201, aimed at treating relapsed/refractory AL amyloidosis. This designation could expedite the development and approval process under current FDA guidelines, allowing for more frequent interactions with the agency. Enrollment in the related NEXICART-2 clinical trial is accelerating, and initial results have shown high complete response rates with no observed neurotoxicity. However, the company faces inherent risks in the ongoing clinical trials as historical approval rates for RMAT applications are low.
Read more →IMMXImmix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
Immix Biopharma has successfully completed the safety run-in segment of the NEXICART-2 study, which evaluates their CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. Following positive data from previous studies, the company is now set to accelerate patient enrollment across U.S. clinical sites starting January 2025. NXC-201 is unique as the only one-time CAR-T therapy in development for this condition, and it has shown encouraging response rates without neurotoxicity in earlier trials. The next program update is anticipated in Q1 2025.
Read more →IMMX▲ +5.7%on this news
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
Immix Biopharma has announced promising results from its NEXICART-2 trial of NXC-201 in relapsed/refractory AL Amyloidosis, with all four treated patients normalizing disease markers within 30 days. Of these patients, two are already classified as complete responders, indicating potential efficacy of the therapy. The company anticipates future updates and believes that the remaining patients may also achieve complete response status soon. This is the first clinical data reported from the U.S. trial, which is currently the only ongoing CAR-T study for AL Amyloidosis in the country.
Read more →IMMXJournal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Immix Biopharma's NXC-201 has shown promising clinical results for relapsed/refractory AL Amyloidosis, with a 75% complete response rate in a study published in the Journal of Clinical Oncology. The therapy demonstrated rapid and deep responses in patients who had undergone multiple prior treatments. The company is advancing its U.S. clinical trial focused on patients with preserved heart function.
Read more →IMMX▼ -13.8%on this news
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Immix Biopharma has reported promising updated results for its CAR-T therapy NXC-201, showing a 75% complete response rate among 16 patients with relapsed/refractory AL amyloidosis. The best response duration reached 31.5 months, indicating significant potential efficacy. These results were presented at the 66th American Society of Hematology Annual Meeting. Despite the positive data, the small patient cohort and the absence of FDA-approved therapies for this condition highlight ongoing uncertainties in the drug's future success.
Read more →IMMXImmix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
Immix Biopharma, Inc. will host a conference call on December 10, 2024, to discuss new positive developments regarding its CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. The update follows initial Phase 1b/2 study results indicating robust clinical responses and the absence of neurotoxicity. The conference will include remarks from management and a Q&A session, providing a platform for investor and analyst inquiries.
Read more →IMMXImmix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
Immix Biopharma presented positive clinical data on its CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, showing a 75% complete response rate among patients. The data will be showcased during the 66th ASH Annual Meeting in December 2024. NXC-201 is noted as the only CAR-T therapy being developed for this condition, with no neurotoxicity observed in trials. The findings highlight significant potential for the treatment within an underserved patient population.
Read more →IMMXImmix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Immix Biopharma has announced significant progress in its NEXICART-2 clinical study of the CAR-T therapy NXC-201 for treating relapsed/refractory AL Amyloidosis. The study has advanced to a dose expansion level of 450 million CAR+T cells after successfully completing a first cohort at 150 million cells, both of which showed complete responses in previous studies. The NXC-201 is notable as it is the only single-use CAR-T treatment being evaluated in the U.S. for this patient population. Overall response rates from earlier international studies have been highly encouraging, indicating strong efficacy potential for NXC-201.
Read more →IMMXImmix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Immix Biopharma has appointed Dr. Raymond Comenzo to its Scientific Advisory Board, enhancing its expertise in AL Amyloidosis. Dr. Comenzo is known for his leading role in the Andromeda trial, which achieved the first FDA-approved therapy for the condition. His involvement is expected to strengthen the development of CAR-T therapy NXC-201, which is currently in clinical trials as a treatment for relapsed/refractory AL Amyloidosis. Immix Biopharma aims to lead in delivering innovative treatments for this underserved patient population.
Read more →IMMXImmix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma has announced the expansion of its clinical trial sites for the NEXICART-2 study, which focuses on CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. New sites include renowned institutions such as the Cleveland Clinic, UC Davis, and Sutter Health, aiming to improve patient access to this innovative treatment. Preliminary data from earlier trials reported a high response rate of 92%. However, the company faces uncertainties in the future success of its trials and funding for ongoing research.
Read more →IMMXCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
Immix Biopharma has received an $8 million grant from the California Institute for Regenerative Medicine to support the clinical development of its CAR-T therapy, NXC-201, for relapsed/refractory AL Amyloidosis. The NEXICART-2 trial aims to evaluate the safety and efficacy of this innovative treatment, which addresses a significant unmet medical need in a rare disease with no current FDA-approved therapies. Preliminary data from earlier studies indicate a high overall response rate, highlighting the potential of NXC-201.
Read more →IMMXCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
Immix Biopharma, Inc. announced that it has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of its CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. The NEXICART-2 trial will investigate the treatment's safety and efficacy in affected patients. Preliminary data from an earlier study indicated promising results, with a 92% overall response rate. However, challenges include uncertainties regarding the ongoing clinical trial results and the advancement to registration studies.
Read more →IMMX▼ -8.5%on this news
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma has announced the dosing of the first patient in its U.S. clinical trial NEXICART-2 for NXC-201, a CAR-T therapy targeting AL Amyloidosis. This milestone aligns with the company's guidance for mid-2024, building upon prior positive data from the international NEXICART-1 study. The drug has shown promising results, achieving a 92% response rate in earlier trials, indicating its potential as a new treatment for patients who have not previously received BCMA-targeted therapy. The study will focus on patients with relapsed/refractory AL Amyloidosis and is set to enroll a total of 40 participants.
Read more →IMMXImmix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma, a clinical-stage biopharmaceutical company, announced its participation in the Stifel 2024 Cell Therapy Forum, where it will present its advancements in cell therapies for autoimmune diseases. The presentation is scheduled for July 9, 2024, and institutional investors will have the opportunity to meet with the IMMX team virtually. The company’s lead candidate, NXC-201, aims to be a groundbreaking CAR-T cell therapy that is currently under evaluation in clinical trials, with the potential to significantly benefit patients. Immix Biopharma has received Orphan Drug Designation for its therapies from both the FDA and EMA, indicating recognition of the potential impact of its treatments.
Read more →IMMXImmix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
Immix Biopharma has announced positive clinical data for its CAR-T therapy NXC-201, showing a 92% overall response rate in patients with relapsed/refractory AL Amyloidosis. In the NEXICART-1 study, 100% of patients without prior BCMA-targeted therapy responded, and notable safety profiles were highlighted, with no cases of significant neurotoxicity. The results, presented at the ASGCT 2024 conference, demonstrate the therapy's potential to address an unmet medical need. The company plans to advance to the NEXICART-2 trial aimed at further evaluating safety and efficacy in this patient population.
Read more →IMMXImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma has been awarded European Orphan Drug Designation for its therapy NXC-201, aimed at treating multiple myeloma. This designation allows for 10 years of market exclusivity and provides regulatory and financial benefits. The CEO emphasizes its potential impact on frail patients, while also acknowledging the risks involved in the ongoing clinical trials. The company hopes NXC-201 can serve as an attractive option for patients who are relapsed or refractory.
Read more →IMMX▼ -11.6%on this news
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma has announced that it is on schedule to initiate dosing for its CAR-T therapy, NXC-201, for relapsed/refractory AL Amyloidosis patients in the U.S. by mid-2024. Clinical trial agreements have already been signed and site initiation visits are set for April and May 2024. The NEXICART-2 trial will focus on patients with adequate cardiac function, further expanding options for this patient population. NXC-201 has also received Orphan Drug Designation from both the FDA and EMA, demonstrating its potential significance in treating this rare disease.
Read more →IMMXImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Immix Biopharma has announced that updated clinical data for their CAR-T therapy NXC-201 has been accepted for oral presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy. The presentation will focus on the therapy's development for patients with relapsed/refractory AL amyloidosis. The NEXICART-1 clinical trial has established a recommended Phase 2 dose and aims to demonstrate NXC-201's efficacy and safety. Immix Biopharma is preparing to submit data to the FDA as more patients complete the trial.
Read more →IMMXImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma has selected Memorial Sloan Kettering Cancer Center as the lead site for its clinical trial of NXC-201, a CAR-T therapy aimed at treating relapsed/refractory AL Amyloidosis. The NEXICART-2 trial is a Phase 1b study expected to enroll 40 patients over 18 months, focusing on the therapy's safety and efficacy. NXC-201 has been recognized for its unique targeting abilities and received Orphan Drug Designation from both the FDA and EMA. Despite the optimism around NXC-201, challenges such as funding and regulatory approvals remain.
Read more →IMMX▼ -8.1%on this news
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Immix Biopharma has launched the "Be Proactive in AL" initiative aimed at raising awareness of AL Amyloidosis, a serious condition often diagnosed late due to its non-specific symptoms. The campaign focuses on educating patients about the importance of early diagnosis and available treatment options. Additionally, it features patient experience videos and provides resources to connect with advocacy. Immix aims to enhance awareness among both patients and healthcare providers to expedite the diagnostic process.
Read more →IMMX▼ -8.1%on this news
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Immix Biopharma has launched the 'Be Proactive in AL' awareness campaign aimed at improving the recognition and diagnosis of AL Amyloidosis. The initiative emphasizes the importance of early diagnosis to prevent organ damage and educates patients about available treatment options. The campaign includes patient experience videos and resources to help those with symptoms seek medical advice.
Read more →IMMXImmix Biopharma 12 Month Review Progress Update
Immix Biopharma, Inc. has reported significant progress in its recent 12-month review, highlighting the accomplishments related to its CAR-T cell therapy, NXC-201. The company received U.S. FDA investigational new drug clearance and Orphan Drug Designations for AL Amyloidosis and multiple myeloma. Clinical data presented at recent conferences showcased promising response rates in patients treated with NXC-201, solidifying Immix's position in the cell therapy space. The company plans to continue quarterly data updates and expand its clinical trials into new autoimmune indications in the upcoming year.
Read more →IMMX▲ +6.6%on this news
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
Immix Biopharma has successfully closed a public offering, raising approximately $15 million through the sale of 5,535,055 shares of common stock at $2.71 per share. The net proceeds from this offering will be utilized for the clinical trials of the company's lead asset, NXC-201, as well as general corporate needs. This financial boost positions the company to advance its research in personalized therapies for oncology and immunology.
Read more →IMMX▲ +7.1%on this newsshared move
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Immix Biopharma has received European Union Orphan Drug Designation for NXC-201, a treatment aimed at relapsed/refractory AL Amyloidosis. This designation provides the company with market exclusivity and various regulatory advantages, which are crucial for the development of therapies for rare diseases. The designation acknowledges the growing incidence of this condition, which is increasingly affecting a significant patient population. Immix's leadership believes that NXC-201 has the potential to be a transformative option for patients with limited existing treatments.
Read more →IMMX▼ -6.3%on this newsshared move
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
Immix Biopharma has announced a public offering of approximately 5.5 million shares of common stock, pricing them at $2.71 each, potentially raising $15 million. The funding will primarily be directed towards clinical trials for its lead cell therapy asset, NXC-201, along with general corporate purposes. The offering is expected to close on February 8, 2024, pending customary conditions. Titan Partners Group is managing the offering, which is conducted under an effective shelf registration statement with the SEC.
Read more →IMMX▼ -19.9%on this newsshared move
Immix Biopharma Announces Proposed Public Offering of Common Stock
Immix Biopharma has announced plans for a proposed public offering of common stock to fund its NXC-201 clinical trials and other corporate purposes. The offering will be exclusively for shares sold by the company itself, with the underwriters receiving an option for additional shares. While a shelf registration statement has been filed and approved by the SEC, the actual completion of the offering will depend on market conditions. The company emphasizes that there are inherent uncertainties regarding the offering's details and timing.
Read more →IMMXImmix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
Immix Biopharma has issued a statement regarding January 2024 FDA labeling changes for CAR-T products, emphasizing the importance of regulatory vigilance. The company highlights the potential of its CAR-T candidate NXC-201 in treating relapsed/refractory AL Amyloidosis and notes its favorable tolerability profile from ongoing clinical trials. Additionally, NXC-201 has received Orphan Drug Designation from the FDA, enhancing its development trajectory. Company executives expressed optimism about the therapy's potential impact on patients and its differentiation in the market.
Read more →IMMXImmix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
Immix Biopharma has appointed Dr. Vaishali Sanchorawala, an expert in AL amyloidosis, to its Scientific Advisory Board for Nexcella. Dr. Sanchorawala brings significant experience with novel treatments for AL amyloidosis, including involvement in the standard of care with daratumumab. Immix Bio asserts that her guidance will be crucial as they advance their CAR-T therapy, NXC-201, which targets relapsed/refractory AL amyloidosis. The company remains optimistic about the potential improvements in patient outcomes with this therapy.
Read more →IMMX▼ -8.9%on this news
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
Immix Biopharma announced that Dr. Marko Radic has joined its subsidiary Nexcella's Scientific Advisory Board. Dr. Radic is a prominent figure in CAR-T cell therapy, with extensive research experience in autoimmune diseases. His contributions are expected to advance Immix's efforts in developing innovative treatments, particularly for autoimmune disorders, leveraging promising clinical data from their lead therapy, NXC-201. The appointment aims to enhance the company's treatment strategies and potential product offerings in the field.
Read more →IMMXImmix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
Immix Biopharma has announced promising results from their Phase 1b/2a NEXICART-1 study of NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL amyloidosis. The therapy demonstrated a remarkable 100% overall response rate and a best response duration of 23.7 months. The data was presented at the recent ASH 2023 meeting, highlighting both safety and efficacy among patients who had previously undergone an average of 6 lines of therapy. This study positions NXC-201 as a potentially transformative treatment option for patients facing dire situations with no approved therapies available.
Read more →IMMXImmix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
Immix Biopharma, Inc. is set to present at the 2023 JMP Securities Hematology and Oncology Summit on December 5, 2023. The virtual event will include institutional investor meetings, enhancing communication with potential investors. Immix is recognized for its innovative personalized therapies, particularly its CAR-T therapy NXC-201, which demonstrates high efficacy in treating certain blood cancers. The company's strategic focus on personalized medicine may position it favorably in the biopharmaceutical landscape.
Read more →IMMX▲ +5%on this news· ran to +26% by day 3
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Immix Biopharma is set to host a virtual KOL event on November 29, 2023, to discuss its BCMA-targeted CAR-T cell therapy candidate NXC-201, focused on relapsed/refractory AL amyloidosis and multiple myeloma. The ongoing clinical trials have shown promising results, including a 100% overall response rate and IND clearance for further dosing in the U.S. NXC-201 has also received Orphan Drug Designation from the FDA, showcasing its potential importance. The event will include presentations from leading experts in the field, emphasizing the therapy's positioning in the current treatment landscape.
Read more →IMMXImmix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
Immix Biopharma has received FDA approval for its IND application for CAR-T NXC-201, allowing the treatment to expand into U.S. sites for patients with relapsed/refractory AL Amyloidosis. The compound has already shown promising results outside the U.S., with notable response rates in clinical studies. The favorable tolerability of NXC-201 could open avenues for treating autoimmune conditions in the future. With multiple U.S. sites planning to enroll, Immix is setting the stage for further advancements in its clinical trials.
Read more →IMMX▲ +20.7%on this news
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
Immix Biopharma announced that its investigational CAR-T therapy NXC-201 data for relapsed/refractory AL Amyloidosis will be presented at the 65th ASH Annual Meeting. The therapy achieved a remarkable 100% overall response rate in patients. The presentation is set for December 10th, and highlights the potential of NXC-201 as a one-time treatment option targeting the root cause of the disease. The company also plans to further develop the therapy with submissions to the FDA based on ongoing clinical trials.
Read more →IMMX▲ +20.7%on this news
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
Immix Biopharma announced that updated clinical data for NXC-201, a CAR-T therapy for relapsed/refractory multiple myeloma, will be presented at the 65th ASH Annual Meeting. The therapy has shown a 95% overall response rate in patients not previously treated with BCMA-targeted therapy. The presentation is scheduled for December 11, 2023, in San Diego.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
Immix Biopharma has announced that Dr. Michaela Liedtke, an expert in hematology and CAR-T therapy, has joined its subsidiary Nexcella's Scientific Advisory Board. Dr. Liedtke, who has considerable experience in clinical trials, will contribute to Nexcella's development of CAR-T therapy, specifically for relapsed/refractory AL amyloidosis and multiple myeloma. Nexcella's lead therapy, NXC-201, has shown promising early clinical results with high response rates.
Read more →IMMXImmix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Immix Biopharma has successfully completed the 3rd engineering batch of its CAR-T cell therapy, NXC-201, at its California manufacturing site. This milestone supports the expansion of their NEXICART-1 clinical trial in the U.S., where NXC-201 has demonstrated a notable 100% overall response rate among relapsed/refractory AL Amyloidosis patients. Company executives express optimism about the potential for NXC-201 to offer outpatient CAR-T therapy access to a wider range of hospitals, currently underutilized due to existing neurotoxicity risks associated with CAR-T treatments.
Read more →IMMX▲ +5.3%on this news
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
Immix Biopharma has reported promising results from its Phase 1b/2a NEXICART-1 clinical trial for NXC-201, an investigational CAR-T cell therapy targeting relapsed/refractory AL amyloidosis. The latest data revealed a 100% overall response rate and a 67% complete response rate among nine heavily pre-treated patients as of September 20, 2023. Immix plans to submit a Biologics License Application (BLA) to the FDA for NXC-201 following the treatment of 30 to 40 patients. NXC-201's unique characteristics may allow it to serve as a viable outpatient treatment, significantly enhancing the current treatment landscape for this challenging condition.
Read more →IMMX▲ +26.6%on this newsshared move
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
Immix Biopharma announced compelling clinical data for its BCMA-targeted CAR-T therapy NXC-201 at the IMS 20th Annual Meeting. The therapy showed a 95% overall response rate in relapsed/refractory multiple myeloma patients without prior exposure to BCMA-targeted therapies. The company aims to submit a Biologics License Application (BLA) to the FDA after treating 100 patients. Overall, the trial demonstrates promise in a segment of patients often excluded from clinical trials, supporting a potential outpatient treatment model.
Read more →IMMX▲ +15.4%on this news
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
Immix Biopharma has received FDA Orphan Drug Designation for its CAR-T therapy, NXC-201, aimed at treating AL amyloidosis. This designation provides significant benefits, including market exclusivity and financial incentives for clinical development. The therapy is currently in a Phase 1b/2a trial, showing promising response rates in patients with relapsed and refractory conditions.
Read more →IMMX▲ +24.2%on this newsshared move
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Immix Biopharma's subsidiary, Nexcella, has successfully completed its second engineering batch of the CAR-T therapy NXC-201 at its U.S. manufacturing site. This milestone supports the expansion of the ongoing NEXICART-1 clinical trial in the U.S., with plans to broaden the application of NXC-201 to earlier lines of therapy. The therapy is particularly notable for its zero neurotoxicity and has shown high response rates in clinical trials. As a result, the company believes it can significantly increase the accessibility of CAR-T therapies.
Read more →IMMXNexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
Immix Biopharma's subsidiary, Nexcella, will present clinical data for its CAR-T therapy, NXC-201, at the Bank of America 2023 Healthcare Trailblazers Conference on October 26, 2023. The company aims to address neurotoxicity issues that currently limit CAR-T therapy adoption. Initial trials have shown promising response rates for multiple myeloma and AL amyloidosis.
Read more →IMMX▲ +12.8%on this newsshared move
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
Immix Biopharma has announced that Dr. Suzanne Lentzsch, a leading expert in multiple myeloma and AL amyloidosis, has joined the Nexcella Scientific Advisory Board. Dr. Lentzsch brings significant experience from her role in clinical trials and her leadership in the National Cancer Institute Myeloma Steering Committee. Her expertise is anticipated to strengthen Nexcella's efforts in developing innovative therapies, including an autologous CAR-T treatment showing encouraging clinical outcomes. The company expresses enthusiasm about collaborating with Dr. Lentzsch to advance patient care in oncology.
Read more →IMMX▲ +11.1%on this news
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
Immix Biopharma has received Orphan Drug Designation from the FDA for NXC-201, a CAR-T cell therapy aimed at treating multiple myeloma. This designation provides financial incentives and potential market exclusivity. NXC-201 has shown promising results without neurotoxicity in clinical trials, enhancing treatment options for patients with this challenging blood cancer.
Read more →IMMX▲ +6.1%on this news· ran to +23% by day 3shared move
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
Immix Biopharma announced the appointment of Dr. Heather Landau to the Nexcella Scientific Advisory Board. Dr. Landau, known for her expertise in CAR-T therapy and plasma cell disorders, aims to enhance treatment options for patients with relapsed/refractory AL amyloidosis and multiple myeloma. Immix's lead CAR-T therapy, NXC-201, has shown promising initial response rates in clinical trials. The addition of Dr. Landau is expected to strengthen the development of innovative treatments within the company.
Read more →IMMXImmix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
Immix Biopharma, Inc. announced its investigational CAR-T therapy NXC-201 for relapsed/refractory AL amyloidosis will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece. The company's Phase 1b portion of the NEXICART-1 clinical trial has successfully identified a recommended Phase 2 dose of 800 million CAR+T cells. Initial response rates of 92% and 100% have been recorded in patients with multiple myeloma and AL amyloidosis, respectively. Immix plans to submit an IND application to the FDA to expand the clinical trial to the U.S.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Nexcella, a subsidiary of Immix Biopharma, announced that its clinical data on NXC-201 for relapsed/refractory multiple myeloma has been accepted for presentation at the 20th International Myeloma Society Annual Meeting in Athens, Greece. The data presentation will provide insights into the safety and efficacy of this investigational CAR-T cell therapy. The ongoing clinical trial aims to determine the recommended dose and measure the efficacy in treating multiple myeloma and AL amyloidosis. Nexcella plans to submit an IND application to the FDA to enhance its clinical trials in the U.S.
Read more →IMMX▼ -6.1%on this news
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Immix Biopharma reported a positive interim update from its IMMINENT-01 trial, where 75% of patients with relapsed/refractory metastatic colorectal cancer showed tumor shrinkage after receiving the IMX-110 and tislelizumab combination treatment. The trial has successfully completed dosing in its second cohort without severe adverse events. As a result, the company is advancing to higher dose cohorts with hopes for improved clinical outcomes. The colorectal cancer market continues to expand, with industry estimates projecting significant growth in the coming years.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Nexcella, a subsidiary of Immix Biopharma, has completed its first engineering batch of CAR-T therapy NXC-201 at its U.S. facility. This milestone supports the expansion of its Phase 1b/2a NEXICART-1 clinical trial targeting relapsed/refractory multiple myeloma and AL amyloidosis. Notably, NXC-201 achieved a 100% response rate among AL amyloidosis patients and 92% for multiple myeloma patients. Furthermore, the therapy aims to reduce hospitalization costs associated with CAR-T treatments, as evidenced by its rapid side-effect onset and duration.
Read more →IMMX▼ -6.9%on this news
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
Nexcella, a subsidiary of Immix Biopharma, has successfully completed a Pre-IND meeting with the FDA for its NXC-201 US clinical trial targeting relapsed/refractory multiple myeloma and AL amyloidosis. The meeting allowed for valuable feedback and guidance from the FDA regarding manufacturing and the upcoming IND application. NXC-201, a chimeric antigen receptor T (CAR-T) therapy, has shown promising response rates in earlier trials, indicating potential for effective outpatient treatment options. The company plans to proceed with submitting an IND application as it aims to expand clinical trials in the U.S.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
Immix Biopharma's subsidiary Nexcella has appointed Edward J. Borkowski, the former CFO of Mylan N.V., to its Board of Directors. With over 30 years of experience in the pharmaceutical and healthcare sectors, Borkowski aims to leverage his expertise in finance and capital markets to support Nexcella's growth and clinical programs. His appointment comes as Nexcella prepares to advance its CAR-T therapy candidate NXC-201 into US clinical trials. The leadership believes that Borkowski's significant background will provide invaluable guidance as they develop novel therapies for oncology.
Read more →IMMX▲ +8.1%on this news· ran to +19% by day 1shared move
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
Nexcella, a subsidiary of Immix Biopharma, has appointed Jeffrey H. Cooper, a former CFO of BioMarin, to its Board of Directors effective June 20, 2023. Cooper brings significant expertise with over 30 years in the pharmaceutical industry and has previously served on the boards of other biopharma firms that have been successfully acquired. His experience in finance and leadership is expected to support Nexcella as it advances its lead candidate, NXC-201, towards clinical trials in the U.S. and seeks regulatory approvals globally.
Read more →IMMX▼ -5.9%on this newsshared move
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
Nexcella, a subsidiary of Immix Biopharma, has appointed Dr. Mary Sue Coleman to its Board of Directors. Dr. Coleman is well-respected for her previous role as an Independent Director at Johnson & Johnson and brings over a decade of related experience. Her proven track record in leading large research-focused institutions is expected to benefit Nexcella as it advances its lead CAR-T cell therapy, NXC-201, through clinical development. Nexcella aims to provide cutting-edge treatments for oncology and other diseases.
Read more →IMMXImmix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Immix Biopharma, Inc. has successfully completed a $5 million at-the-market equity offering program. The company plans to utilize the proceeds to fund ongoing clinical trials for its IMX-110 monotherapy and combination therapy with tislelizumab, as well as for general corporate purposes. ImmixBio highlights its pioneering work in CAR-T cell therapies and the promising response rates of its lead assets, NXC-201 and IMX-110, in multiple myeloma and AL amyloidosis. Overall, the completion of this funding round reflects confidence in the company's strategic development plans.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
Nexcella, a subsidiary of Immix Biopharma, has appointed Henry A. McKinnell, Jr., former chairman and CEO of Pfizer, to its Board of Directors. McKinnell brings over 35 years of experience in the biopharmaceutical sector, including his role in the strategic growth of other pharmaceutical companies. His insights are expected to be invaluable as Nexcella progresses its lead candidate, NXC-201, through clinical development for AL amyloidosis and multiple myeloma. The appointment is seen as a strategic move to enhance the company's leadership and operational capabilities in drug development.
Read more →IMMX▲ +9.4%on this news· ran to +29% by day 1
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
Immix Biopharma's subsidiary Nexcella has announced the start of CAR-T NXC-201 engineering batches at its U.S. manufacturing facility. This milestone supports the expansion of its ongoing NEXICART-1 clinical trial to the United States. NXC-201 is a BCMA-targeted CAR-T therapy that has shown promising response rates in patients with relapsed or refractory multiple myeloma and AL amyloidosis. With the goal of bringing this innovative therapy to U.S. patients, Nexcella is scheduled to submit an IND application to the FDA for its expanded clinical trials.
Read more →IMMX▲ +6.7%on this news
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
Immix Biopharma announced positive clinical results for its CAR-T therapy NXC-201 at the ASGCT meeting, specifically targeting DARZALEX-relapsed/refractory AL Amyloidosis. The study showed a remarkable 100% overall response rate among eight patients, with 63% achieving complete responses. Importantly, no severe cytokine release syndrome (CRS) events were observed, indicating good tolerability. The data suggests NXC-201 may offer a considerable advancement in treatment options for AL Amyloidosis patients who have limited success with existing therapies.
Read more →IMMXImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
Immix Biopharma, Inc. announced that updated clinical data for NXC-201 has been accepted for an oral presentation at the 26th Annual Meeting of the American Society of Gene & Cell Therapy. The presentation will highlight NXC-201's potential as a treatment for relapsed or refractory multiple myeloma and AL amyloidosis. The clinical trial has successfully determined the recommended Phase 2 dose, and plans for an IND application to the FDA are underway to expand the clinical trial in the U.S.
Read more →IMMXImmix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
Immix Biopharma announced early positive data from its clinical trial involving IMX-110 in combination with BeiGene/Novartis anti-PD-1 antibody tislelizumab. In the initial cohort of its ongoing IMMINENT-01 trial, 100% tumor shrinkage was observed in two evaluable patients with advanced metastatic colorectal cancer. This initial success may indicate the potential for IMX-110 in enhancing immune responses against cancer. Additionally, the trial showed no dose limiting toxicities, allowing further patient enrollments at higher doses.
Read more →IMMX▲ +14.4%on this news
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
Immix Biopharma, Inc. announced that it has no financial exposure to Silicon Valley Bank or Silvergate Bank. This statement ensures that the company’s operations remain stable amid ongoing financial uncertainties in the banking sector. Immix Biopharma continues to focus on its clinical-stage development of Tissue-Specific Therapeutics, targeting oncology and immuno-dysregulated diseases. The announcement reflects the company's robust financial position and commitment to its innovative therapeutic solutions.
Read more →IMMXImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
Immix Biopharma, Inc. will present recent clinical data on NXC-201, a CAR-T therapy targeting AL amyloidosis and multiple myeloma, at the 35th Annual Roth Conference. Positive clinical outcomes include a 90% overall response rate in patients with relapsed multiple myeloma and a 100% complete response rate in AL amyloidosis. The findings highlight the potential of NXC-201 as a promising outpatient therapy due to its reduced toxicity profile.
Read more →IMMXImmix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
Nexcella, a subsidiary of Immix Biopharma, has entered into a manufacturing agreement with a U.S. GMP cell therapy manufacturer to support the NXC-201 Phase 1b/2 clinical trial for multiple myeloma and AL amyloidosis. The agreement facilitates the expansion of the ongoing trial in Israel to the United States and is essential for submitting an Investigational New Drug application to the FDA. Promising initial clinical data suggests that NXC-201 could be a groundbreaking outpatient CAR-T therapy.
Read more →IMMX▼ -16.6%on this news
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Immix Biopharma's subsidiary, Nexcella, presented promising interim results for NXC-201 at the 5th European CAR T-cell Meeting. The therapy demonstrated a 90% overall response rate in patients with relapsed or refractory multiple myeloma, with 59% achieving complete or stringent complete response. Notably, the treatment was well-tolerated, exhibiting manageable side effects. NXC-201 is positioned as a potential outpatient CAR-T therapy and is being further developed for regulatory submission planned for early 2025.
Read more →IMMX▼ -8%on this newsshared move
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
Immix Biopharma has announced the dosing of the first two patients in its Phase 1b/2a clinical trial of IMX-110 in combination with BeiGene/Novartis' anti-PD-1 Tislelizumab. This trial aims to enhance responses in patients with advanced solid tumors by converting immunologically 'cold' tumors into 'hot' tumors. Initial clinical data from the trial is expected in the first half of 2023. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, further accelerating its potential approval pathway.
Read more →IMMXImmix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
Immix Biopharma has announced the dosing of an additional patient in its ongoing Phase 1b/2a clinical trial for IMX-110, a novel therapeutic targeting advanced solid tumors. Positive safety data has facilitated the continuing enrollment of patients in the trial, with clinical data expected to be shared on a rolling basis. The FDA has granted orphan drug designation and rare pediatric disease designation for IMX-110, further accelerating its potential development in the treatment of soft tissue sarcoma and rhabdomyosarcoma.
Read more →IMMX▼ -8.2%on this news
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
Nexcella, Inc. announced that its NXC-201 treatment has shown a 100% complete response rate in six relapsed/refractory AL amyloidosis patients. The data, published in Clinical Cancer Research, also highlights a notable reduction in NT-proBNP levels and improved NYHA stages among the patients. With no severe Cytokine Release Syndrome observed, NXC-201 may represent a groundbreaking outpatient CAR-T therapy. The ongoing clinical trials continue to explore its safety and efficacy in treating this rare condition.
Read more →IMMX▼ -5.1%on this news
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
16th patient dosed with IMX-110 to date This is the second patient dosed with IMX-110 in December 2022 Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS AN
Read more →IMMXImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
Tislelizumab supplied by BeiGene as part of ImmixBio’s Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors IMX-110 + Tislelizumab clinical trial data expected to be released on a rolling basis beginning in Q1 2023;
Read more →IMMX▲ +23.3%on this newsshared move
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complet
Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) Multiple Myeloma - 85% overall response rate (71%
Read more →IMMXImmix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
In December 2022, the 15th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110
Read more →IMMX▲ +7.9%on this news· ran to +42% by day 3shared move
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it
Read more →IMMX▲ +16.7%on this news· ran to +55% by day 3
Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher
Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2
Read more →IMMXImmix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmac
Read more →IMMXImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT
Read more →IMMXImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A phot
Read more →IMMX▲ +30.1%on this news· ran to +62% by day 3
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs IMX-
Read more →IMMXImmix Biopharma Announces Share Repurchase Program
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its boa
Read more →IMMX▼ -22%on this news
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDay Management discussed financial position, milestones, and new opportunities presented by current market volatility ImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022 (
Read more →IMMX▼ -10.9%on this news
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announce
Read more →IMMX▼ -9.5%on this news
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The inflammatory bowel disease market is expected to reach $21.4 billion by 2024 f
Read more →IMMX▲ +13.5%on this news
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has
Read more →IMMXImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of IMX-110 is availabl
Read more →IMMXImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles 100% of patients treated with IMX-110 completed planned treatment cycles withou
Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical t
Read more →IMMX▲ +18.4%on this news
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy
IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study ABOVE IMAGE: IMX-110 Surpasses Standard of Care in Mice Cancer Study BELOW IMAGE: Immix Biopharma, Inc. (NASDAQ:IMMX) ANGELES, Jan. 12, 2022 (GLOBE
Read more →IMMX▼ -18.7%on this news
Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders
Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the IMMX Invest
Read more →IMMX▲ +62.4%on this newsshared move
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children Rare Pediatric Disease Designation ("RPDD") quali
Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children ANGELES, January 3, 2021 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"),
Read more →IMMX▼ -18.7%on this news
Immix Biopharma, Inc. Announces Closing of Initial Public Offering
LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of
Read more →IMMXImmix Biopharma, Inc. Announces Pricing of Initial Public Offering
Biopharma, Inc. Announces Pricing of Initial Public Offering ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-
Read more →Competitive Position
How IMMX ranks across every disease it competes inCompetitive Position is a premium feature
See how IMMX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial